HEADER HYDROLASE/INHIBITOR 14-JUL-21 7RFW TITLE STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH A COVALENT TITLE 2 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: 3C-LIKE PROTEINASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: 3CL-PRO, 3CLP, MAIN PROTEASE, MPRO, NON-STRUCTURAL PROTEIN COMPND 5 5, NSP5, SARS CORONAVIRUS MAIN PROTEINASE; COMPND 6 EC: 3.4.22.69; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS SOURCE 3 2; SOURCE 4 ORGANISM_COMMON: 2019-NCOV; SOURCE 5 ORGANISM_TAXID: 2697049; SOURCE 6 GENE: REP, 1A-1B; SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS PROTEASE SARS-COV-2 COVALENT COMPLEX INHIBITOR, HYDROLASE-INHIBITOR KEYWDS 2 COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR S.E.GREASLEY,R.A.FERRE,W.LIU,A.E.STEWART REVDAT 4 05-JAN-22 7RFW 1 JRNL REVDAT 3 22-DEC-21 7RFW 1 COMPND HETNAM HETSYN FORMUL REVDAT 2 17-NOV-21 7RFW 1 JRNL REVDAT 1 10-NOV-21 7RFW 0 JRNL AUTH D.R.OWEN,C.M.N.ALLERTON,A.S.ANDERSON,L.ASCHENBRENNER, JRNL AUTH 2 M.AVERY,S.BERRITT,B.BORAS,R.D.CARDIN,A.CARLO,K.J.COFFMAN, JRNL AUTH 3 A.DANTONIO,L.DI,H.ENG,R.FERRE,K.S.GAJIWALA,S.A.GIBSON, JRNL AUTH 4 S.E.GREASLEY,B.L.HURST,E.P.KADAR,A.S.KALGUTKAR,J.C.LEE, JRNL AUTH 5 J.LEE,W.LIU,S.W.MASON,S.NOELL,J.J.NOVAK,R.S.OBACH,K.OGILVIE, JRNL AUTH 6 N.C.PATEL,M.PETTERSSON,D.K.RAI,M.R.REESE,M.F.SAMMONS, JRNL AUTH 7 J.G.SATHISH,R.S.P.SINGH,C.M.STEPPAN,A.E.STEWART,J.B.TUTTLE, JRNL AUTH 8 L.UPDYKE,P.R.VERHOEST,L.WEI,Q.YANG,Y.ZHU JRNL TITL AN ORAL SARS-COV-2 M PRO INHIBITOR CLINICAL CANDIDATE FOR JRNL TITL 2 THE TREATMENT OF COVID-19. JRNL REF SCIENCE V. 374 1586 2021 JRNL REFN ESSN 1095-9203 JRNL PMID 34726479 JRNL DOI 10.1126/SCIENCE.ABL4784 REMARK 2 REMARK 2 RESOLUTION. 1.73 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.73 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 55.93 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 69.7 REMARK 3 NUMBER OF REFLECTIONS : 19549 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.196 REMARK 3 R VALUE (WORKING SET) : 0.195 REMARK 3 FREE R VALUE : 0.227 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 989 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.73 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.82 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 10.00 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : NULL REMARK 3 BIN R VALUE (WORKING + TEST SET) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2258 REMARK 3 BIN FREE R VALUE : 0.2223 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 23 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2367 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 35 REMARK 3 SOLVENT ATOMS : 139 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 33.25 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.00160 REMARK 3 B22 (A**2) : -0.41430 REMARK 3 B33 (A**2) : 0.41590 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.24870 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.260 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.199 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.159 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.198 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.159 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.951 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.943 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2492 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 3425 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 826 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : 420 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2458 ; 10.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 321 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2092 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.01 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.67 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 15.29 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7RFW COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 15-JUL-21. REMARK 100 THE DEPOSITION ID IS D_1000258185. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 06-OCT-20 REMARK 200 TEMPERATURE (KELVIN) : 98 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 9M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : AUTOPROC REMARK 200 DATA SCALING SOFTWARE : STARANISO REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19549 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.729 REMARK 200 RESOLUTION RANGE LOW (A) : 55.930 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 69.8 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 10.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.73 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.88 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: BUSTER REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 38.36 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.00 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 25.0% W/V PEG1500, 0.1 M MMT, PH 6.0, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 57.31000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 26.55000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 57.31000 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 26.55000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3180 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25120 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -16.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A 625 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 0 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 33 -134.06 55.29 REMARK 500 ASN A 51 74.50 -162.51 REMARK 500 ASN A 84 -114.73 51.22 REMARK 500 TYR A 154 -84.66 42.97 REMARK 500 REMARK 500 REMARK: NULL DBREF 7RFW A 1 306 UNP P0DTD1 R1AB_SARS2 3264 3569 SEQADV 7RFW GLY A 0 UNP P0DTD1 EXPRESSION TAG SEQRES 1 A 307 GLY SER GLY PHE ARG LYS MET ALA PHE PRO SER GLY LYS SEQRES 2 A 307 VAL GLU GLY CYS MET VAL GLN VAL THR CYS GLY THR THR SEQRES 3 A 307 THR LEU ASN GLY LEU TRP LEU ASP ASP VAL VAL TYR CYS SEQRES 4 A 307 PRO ARG HIS VAL ILE CYS THR SER GLU ASP MET LEU ASN SEQRES 5 A 307 PRO ASN TYR GLU ASP LEU LEU ILE ARG LYS SER ASN HIS SEQRES 6 A 307 ASN PHE LEU VAL GLN ALA GLY ASN VAL GLN LEU ARG VAL SEQRES 7 A 307 ILE GLY HIS SER MET GLN ASN CYS VAL LEU LYS LEU LYS SEQRES 8 A 307 VAL ASP THR ALA ASN PRO LYS THR PRO LYS TYR LYS PHE SEQRES 9 A 307 VAL ARG ILE GLN PRO GLY GLN THR PHE SER VAL LEU ALA SEQRES 10 A 307 CYS TYR ASN GLY SER PRO SER GLY VAL TYR GLN CYS ALA SEQRES 11 A 307 MET ARG PRO ASN PHE THR ILE LYS GLY SER PHE LEU ASN SEQRES 12 A 307 GLY SER CYS GLY SER VAL GLY PHE ASN ILE ASP TYR ASP SEQRES 13 A 307 CYS VAL SER PHE CYS TYR MET HIS HIS MET GLU LEU PRO SEQRES 14 A 307 THR GLY VAL HIS ALA GLY THR ASP LEU GLU GLY ASN PHE SEQRES 15 A 307 TYR GLY PRO PHE VAL ASP ARG GLN THR ALA GLN ALA ALA SEQRES 16 A 307 GLY THR ASP THR THR ILE THR VAL ASN VAL LEU ALA TRP SEQRES 17 A 307 LEU TYR ALA ALA VAL ILE ASN GLY ASP ARG TRP PHE LEU SEQRES 18 A 307 ASN ARG PHE THR THR THR LEU ASN ASP PHE ASN LEU VAL SEQRES 19 A 307 ALA MET LYS TYR ASN TYR GLU PRO LEU THR GLN ASP HIS SEQRES 20 A 307 VAL ASP ILE LEU GLY PRO LEU SER ALA GLN THR GLY ILE SEQRES 21 A 307 ALA VAL LEU ASP MET CYS ALA SER LEU LYS GLU LEU LEU SEQRES 22 A 307 GLN ASN GLY MET ASN GLY ARG THR ILE LEU GLY SER ALA SEQRES 23 A 307 LEU LEU GLU ASP GLU PHE THR PRO PHE ASP VAL VAL ARG SEQRES 24 A 307 GLN CYS SER GLY VAL THR PHE GLN HET 4WI A 401 68 HETNAM 4WI (1R,2S,5S)-N-{(1E,2S)-1-IMINO-3-[(3S)-2-OXOPYRROLIDIN- HETNAM 2 4WI 3-YL]PROPAN-2-YL}-6,6-DIMETHYL-3-[3-METHYL-N- HETNAM 3 4WI (TRIFLUOROACETYL)-L-VALYL]-3-AZABICYCLO[3.1.0]HEXANE- HETNAM 4 4WI 2-CARBOXAMIDE HETSYN 4WI PF-07321332, BOUND FORM; NIRMATRELVIR, BOUND FORM; HETSYN 2 4WI PAXLOVID, BOUND FORM FORMUL 2 4WI C23 H34 F3 N5 O4 FORMUL 3 HOH *139(H2 O) HELIX 1 AA1 SER A 10 GLY A 15 1 6 HELIX 2 AA2 HIS A 41 CYS A 44 5 4 HELIX 3 AA3 GLU A 47 ASN A 51 5 5 HELIX 4 AA4 ASN A 53 ARG A 60 1 8 HELIX 5 AA5 LYS A 61 HIS A 64 5 4 HELIX 6 AA6 ILE A 200 ASN A 214 1 15 HELIX 7 AA7 THR A 226 TYR A 237 1 12 HELIX 8 AA8 THR A 243 LEU A 250 1 8 HELIX 9 AA9 LEU A 250 GLY A 258 1 9 HELIX 10 AB1 ALA A 260 GLY A 275 1 16 HELIX 11 AB2 THR A 292 GLY A 302 1 11 SHEET 1 AA1 7 VAL A 73 LEU A 75 0 SHEET 2 AA1 7 PHE A 66 ALA A 70 -1 N VAL A 68 O LEU A 75 SHEET 3 AA1 7 MET A 17 CYS A 22 -1 N THR A 21 O LEU A 67 SHEET 4 AA1 7 THR A 25 LEU A 32 -1 O LEU A 27 N VAL A 20 SHEET 5 AA1 7 VAL A 35 PRO A 39 -1 O TYR A 37 N LEU A 30 SHEET 6 AA1 7 VAL A 86 VAL A 91 -1 O LEU A 87 N CYS A 38 SHEET 7 AA1 7 VAL A 77 GLN A 83 -1 N SER A 81 O LYS A 88 SHEET 1 AA2 5 LYS A 100 PHE A 103 0 SHEET 2 AA2 5 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA2 5 VAL A 148 ASP A 153 -1 N ASN A 151 O SER A 158 SHEET 4 AA2 5 THR A 111 TYR A 118 -1 N SER A 113 O PHE A 150 SHEET 5 AA2 5 SER A 121 ALA A 129 -1 O CYS A 128 N PHE A 112 SHEET 1 AA3 3 LYS A 100 PHE A 103 0 SHEET 2 AA3 3 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA3 3 HIS A 172 THR A 175 -1 O ALA A 173 N MET A 165 LINK SG CYS A 145 C3 4WI A 401 1555 1555 1.92 CRYST1 114.620 53.100 45.460 90.00 102.61 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.008724 0.000000 0.001952 0.00000 SCALE2 0.000000 0.018832 0.000000 0.00000 SCALE3 0.000000 0.000000 0.022541 0.00000